These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30850934)

  • 1. Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes.
    Guerci B; Chanan N; Kaur S; Jasso-Mosqueda JG; Lew E
    Diabetes Ther; 2019 Apr; 10(2):437-449. PubMed ID: 30850934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
    Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
    Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore.
    Cheen HH; Lim SH; Huang MC; Bee YM; Wee HL
    Clin Ther; 2014 Jul; 36(7):1043-53. PubMed ID: 24913030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes.
    Slabaugh SL; Bouchard JR; Li Y; Baltz JC; Meah YA; Moretz DC
    Adv Ther; 2015 Dec; 32(12):1206-21. PubMed ID: 26563324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes.
    Banerji MA; Dunn JD
    Am Health Drug Benefits; 2013 Sep; 6(7):382-92. PubMed ID: 24991370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding adherence to medications in type 2 diabetes care and clinical trials to overcome barriers: a narrative review.
    Tiktin M; Celik S; Berard L
    Curr Med Res Opin; 2016; 32(2):277-87. PubMed ID: 26565758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to therapies in patients with type 2 diabetes.
    García-Pérez LE; Alvarez M; Dilla T; Gil-Guillén V; Orozco-Beltrán D
    Diabetes Ther; 2013 Dec; 4(2):175-94. PubMed ID: 23990497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.
    Hamersky CM; Fridman M; Gamble CL; Iyer NN
    Diabetes Ther; 2019 Jun; 10(3):865-890. PubMed ID: 31054132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
    Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
    Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving medication adherence among patients with type 2 diabetes.
    Meece J
    J Pharm Pract; 2014 Apr; 27(2):187-94. PubMed ID: 24375997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
    Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
    Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
    Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
    Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence and Persistence to Basal Insulin Among People with Type 2 Diabetes in Europe: A Systematic Literature Review and Meta-analysis.
    Gimeno EJ; Bøgelund M; Larsen S; Okkels A; Reitzel SB; Ren H; Orozco-Beltran D
    Diabetes Ther; 2024 May; 15(5):1047-1067. PubMed ID: 38520604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.
    Lokhandwala T; Smith N; Sternhufvud C; Sörstadius E; Lee WC; Mukherjee J
    J Med Econ; 2016; 19(3):203-12. PubMed ID: 26473990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes.
    Goldstein HH
    Postgrad Med; 2008 Sep; 120(3):172-9. PubMed ID: 18824835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.